

Avacta Life Sciences Limited – Patents Summary**Use of Stefin A as a Scaffold Protein (based on application number PCT/GB2006/002115)****Priority Date: 10 June 2005**

<i>Country</i>	<i>Application/Grant no.</i>		<i>Grant Date</i>
Australia	2006256530	Granted	4 April 2013
Canada	2,610,976	Allowed	
Europe	1904529	Granted	11 August 2010
Japan	4989638	Granted	11 May 2012
USA	8,481,491	Granted	9 July 2013
USA Divisional	8,063,019	Granted	22 November 2011

EP1904529 is granted and in force in the following European territories:

Austria	France
Switzerland	UK
Germany	Italy
Denmark	The Netherlands
Spain	Sweden

Modified Stefin A Scaffold Proteins (based on application number PCT/GB2009/050380)**Priority Date: 18 April 2008**

<i>Country</i>	<i>Application/Grant no.</i>	<i>Status</i>	<i>Grant Date</i>
Canada	2,757,513	Pending	
China	102056942B	Granted	31 May 2017
Europe	2279205	Granted	17 August 2016
Japan	5688362	Granted	30 January 2015
USA	8,853,131	Granted	7 October 2014
USA Divisional	9,447,170	Granted	20 September 2016

EP2279205 is granted and in force in the following European territories:

<u>Austria</u>	<u>Greece</u>
<u>Belgium</u>	<u>Hungary</u>
<u>Switzerland</u>	<u>Italy</u>
<u>Germany</u>	<u>The Netherlands</u>
<u>Denmark</u>	<u>Norway</u>
<u>Spain</u>	<u>Poland</u>
<u>Finland</u>	<u>Portugal</u>
<u>France</u>	<u>Sweden</u>
<u>UK</u>	<u>Ireland</u>

Scaffold Proteins derived from Plant Cystatins (based on application number PCT/GB2014/050435)**Priority Date: 14 February 2013****Applicant: Exclusive licensee with University of Leeds**

<i>Country</i>	<i>Application/Grant no.</i>	<i>Status</i>	<i>Grant Date</i>
Australia	2014217628	Granted	10 August 2017
Australia - Div	2017206237	Granted	23 August 2019
Canada	2,900,745	Pending	
China	2014800220705	Pending	
Europe	EP2956156	Granted	18 March 2020
Europe Divisional	EP20163413.6	Pending	
Hong Kong	16105949.3	Pending	
Japan	2015-557514	Pending	
Japan - Divisional	2019-132489	Pending	

24 September 2020

USA	9,932,575	Granted	3 April 2018
USA - Divisional	15/904,069	Allowed	

EP2956156 is granted and in force in the following European territories:

Sweden
Italy
UK
France
Spain
Germany
Switzerland

Scaffold Proteins (based on application number PCT/GB2018/051855)

Priority Date: 7 July 2017

<i>Country</i>	<i>Application/Grant no.</i>	<i>Status</i>	<i>Grant Date</i>
Australia	2018295447	Pending	
Canada	3,067,682	Pending	
China	2018800583340	Pending	
Europe	18740273	Pending	
Hong Kong	62020009496.4	Pending	
Israel	271340	Pending	
Japan	JP2019-570496	Pending	
South Korea	10-2020-7002753	Pending	
Singapore	11201912298Q	Pending	
Taiwan	107123473	Pending	
USA	16/623,680	Pending	

FAP-Activated Therapeutic Agents, and uses related thereto (based on application number PCT/US15/35800 and PCT/US15/35798)

Priority date: 13 June 2014

Exclusive licensee with Bach/Trustees of Tufts College

<i>Country</i>	<i>Application/Grant no.</i>	<i>Status</i>	<i>Grant Date</i>
USA	9,737,556	Granted	22 August 2017
USA	10,117,887	Granted	6 November 2018
USA	10,709,722	Granted	14 July 2020
USA	16/894227	Pending	
China	201580043350.9	Pending	
Canada	2,952,051	Pending	
Europe	15807049	Pending	
Israel	249370	Pending	
USA	10,245,248	Granted	2 April 2019
USA	16/274387	Pending	
Hong Kong	17109290.9	Pending	
Japan	6744826	Granted	4 August 2020
Japan	2020-130483	Pending	

FAP-Activated Proteasome Inhibitors for Treating Solid Tumors (based on application number PCT/US12/053140).

Priority date: 30 August 2011

Exclusive licensee with Bach/Trustees of Tufts College

<i>Country</i>	<i>Application/Grant no.</i>	<i>Status</i>	<i>Grant Date</i>
Australia	2012301810	Granted	14 September 2017
Canada	2846852	Allowed	
Europe	12827686.2	Pending	

24 September 2020

Japan	6207509	Granted	4 October 2017
China	201810059355.6	Pending	
USA	9597410	Granted	21 March 2017
USA Cont.	9956297	Granted	1 May 2018
USA Cont.	10517955	Granted	31 December 2019
USA Cont.	16/688574	Pending	

Combination therapies using Immuno-Dash inhibitors and PGE2 antagonists (based on application number PCT/US17/50474 and combination therapies using Caspase-1 dependent anticancer agents and pge2 antagonists based on application number PCT/US18/26470).

Priority date: 7 April 2017; 7 September 2017

Exclusive licensee with Bach/Trustees of Tufts College

<i>Country</i>	<i>Application/Grant no.</i>	<i>Status</i>	<i>Grant Date</i>
USA	16/603502	Pending	
USA	16/331,346	Pending	
China	2017800068517.6	Pending	
Canada	3,036,202	Pending	
Europe	3509604	Pending	
Japan	2019-513333	Pending	
South Korea	10-2019-7009726	Pending	

Tumor Microenvironment -Activated Drug-Binder Conjugates, and used related thereto (based on application number PCT/US19/35374)

Priority Date: 4 June 2018

Patent application is jointly owned between Avacta and Trustees of Tufts College

<i>Country</i>	<i>Application/Grant no.</i>		<i>Grant Date</i>
PCT	PCT/US19/35374	Pending	
Taiwan	108119354	Pending	

PDL1 Binding Affimers and uses related thereto (based on application number PCT/EP2019/059354)

Priority Date: 11 April 2018

<i>Country</i>	<i>Application/Grant no.</i>		<i>Grant Date</i>
United Kingdom	GB1805963.4	Pending	
PCT	PCT/EP2019/059354	Pending	
Taiwan	108112713	Pending	
Australia	2019253221	Pending	
Canada			
China			
Europe	19725277.8	Pending	
Israel			
India			
Japan			
South Korea			
Singapore	11202008725Y	Pending	
United States			